Who are L-folinic's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Levo-Leucovorin, Calcium folinate (LV), L-leucovorin, L-folinic acid.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/l-folinic.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-15 · How we verify

L-folinic — Competitive Intelligence Brief

L-folinic (L-folinic) competitive landscape: 4 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Reduced folate cofactor / Chemotherapy adjuvant. Area: Oncology.

phase 3 Reduced folate cofactor / Chemotherapy adjuvant Thymidylate synthase (indirect) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

L-folinic (L-folinic) — UNICANCER. L-folinic acid (leucovorin) is a reduced form of folic acid that enhances the activity of fluorouracil-based chemotherapy by stabilizing the ternary complex between fluorodeoxymonophosphate, thymidylate synthase, and the cofactor.

Comparator set (4 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
L-folinic TARGET	L-folinic	UNICANCER	phase 3	Reduced folate cofactor / Chemotherapy adjuvant	Thymidylate synthase (indirect)
Levo-Leucovorin	Levo-Leucovorin	Fujian Cancer Hospital	phase 3	Reduced folate cofactor / Chemotherapy adjuvant	Thymidylate synthase (indirect)
Calcium folinate (LV)	Calcium folinate (LV)	Multicenter Clinical Study Group of Osaka, Colorectal Cancer Treatment Group	phase 3	Reduced folate cofactor / Chemotherapy adjuvant	Thymidylate synthase (indirect, via 5-FU potentiation)
L-leucovorin	L-leucovorin	Gruppo Oncologico del Nord-Ovest	phase 3	Reduced folate cofactor / chemotherapy adjuvant	Thymidylate synthase (indirect; acts as cofactor)
L-folinic acid	L-folinic acid	The Christie NHS Foundation Trust	phase 3	Reduced folate cofactor / Chemotherapy adjuvant	Thymidylate synthase (indirect), one-carbon metabolism

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Reduced folate cofactor / Chemotherapy adjuvant class)

Fujian Cancer Hospital · 1 drug in this class
Multicenter Clinical Study Group of Osaka, Colorectal Cancer Treatment Group · 1 drug in this class
The Christie NHS Foundation Trust · 1 drug in this class
UNICANCER · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). L-folinic — Competitive Intelligence Brief. https://druglandscape.com/ci/l-folinic. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab